Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib

Acquired resistance to fulvestrant and palbociclib is a new challenge to treatment of estrogen receptor positive (ER+) breast cancer. ER is expressed in most resistance settings; thus, bromodomain and extra-terminal protein inhibitors (BETi) that target BET-amplified ER-mediated transcription have t...

詳細記述

保存先:
書誌詳細
出版年:J Med Chem
主要な著者: Li, Yangfeng, Zhao, Jiong, Gutgesell, Lauren M., Shen, Zhengnan, Ratia, Kiira, Dye, Katherine, Dubrovskyi, Oleksii, Zhao, Huiping, Huang, Fei, Tonetti, Debra A., Thatcher, Gregory R. J., Xiong, Rui
フォーマット: Artigo
言語:Inglês
出版事項: 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8258866/
https://ncbi.nlm.nih.gov/pubmed/32453591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.0c00456
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料